CHEK2 and breast cancer: Consistent with literature, CHEK2 c.1100delC as well as TP53 mutant BC patients had shorter disease-free survival (DFS) compared with BC patients wild-type for both alleles (CHEK2: HR = 2.26, 95% CI = 1.40–3.65, P = 8.2*10−4; TP53: HR = 1.30, 95% CI = 1.01–1.67, P = 0.039; Fig. 4B).